Invicro has acquired Imanova in a move that bolsters the company’s biomedical imaging capabilities and gives it a foothold to expand its services into Europe.
The biometrics contract research organization (CRO) and clinical trial software provider is continuing with its expansions plans as it opens a new office in King of Prussia, Pennsylvania.
The mid-size contract research organization (CRO) sector continues to evolve and surprise experts with rich valuations – and what seems to be a never ending list of transactions.
Eurofins Pharma Bioanalytical Services has launched a consulting program to support clients conducting large molecule preclinical and clinical studies.
Researchers have developed and tested a method to determine how relevant mouse models are to human disease to better enable comparison of pharmacological targets across species.
Cancer Genetics’ acquisition of vivoPharm expands its geographical footprint, customer base, and diversifies its business model beyond fee for service, says CEO.
Charles River Laboratories has acquired Brains On-Line in an ongoing effort to deepen its drug discovery capabilities and build out its portfolio through strategic acquisitions.
BioreclamationIVT has acquired the biospecimen and research services provider, Asterand Bioscience, following the purchase of TransCell Science earlier this year.
Evotec and Fraunhofer IME-SP have signed a strategic collaboration to advance Evotec’s patient-derived iPSC platform and subsequent drug discovery projects.
Boehringer Ingelheim and Philogen have signed a multi-target research agreement to discover and optimize new small molecule therapeutics for unmet medical needs.
Takeda Pharmaceutical Company Limited and Schrödinger Inc. have formed a multi-target research collaboration that leverages Schrödinger’s in silico platform-driven drug discovery capabilities.
Bioclinica has announced that the safety software company AB Cube has joined its eHealth App xChange – and is touting its platform as “the future of pharmacovigilance.”
SQI Diagnostics Inc. has signed an agreement to commercialize a custom multiplexed assay for a Waltham, MA-based global biotechnology company's blood disorder drug program.
The pharmaceutical industry and regulators are preparing for Brexit and how to best “manage and mitigate” any potential risks the UK’s departure from the EU may pose.
EQT's acquisition of Certara is a bet on the continued convergence of healthcare and technology as the industry further adopts biosimulation to advance drug development.
The preclinical CRO Pharmatest has developed an animal model to clarify the role of human immune cells in bone metastases using Taconic Biosciences’ huNOG model.
Spheryx, Inc. has been awarded a $1.5m grant over two years to support modifications to the company’s propriety protein aggregation detection and monitoring technology.
Biogen and Accenture Labs have collaborated to develop a quantum-enabled molecular comparison application to accelerate drug discovery and ultimately, time to clinic.
Evotec has joined a consortium through which it gains access to a sample biobank in order to perform drug discovery based on unique kidney disease patient cohorts.
Dutch scientists have developed a microgel chip that is capable of holding single cells for analysis and research for far longer than currently available 3D culturing technologies.
Experts are calling for an increased focus on human cellular model development after animal tests failed to detect the toxicity of an experimental drug before the first-in-human clinical trial that left one dead.
Forty mice were launched into space last week aboard the SpaceX Dragon, which will deliver the genetically engineered research models to the International Space Station for study in microgravity.
Evotec AG has received a payment of approximately €5m ($5.62m) as part of its strategic alliance with Bayer – which the company says is “well on track and very successful.”
Charles River Laboratories International, Inc. has partnered with OcellO to expand its PDX model capabilities and has made several additions to its online Tumor Model Compendium.
Sanofi and Artificial Intelligence (AI)-driven Exscientia have announced a €250m ($271.9m) drug target research collaboration and licence option agreement.
EyeCRO and MPI Research are co-developing large mammalian preclinical models for ophthalmic diseases as clients look to perform pharmacology studies in larger species.
AMRI has received a 5-year federal contract award from the National Institutes of Health (NIH) under which it will provide drug substance development and manufacturing services.
Plasticell is advancing multiple projects through which it will develop and manufacture red blood cell substitutes for human clinical transfusion and progress preclinical trials.
Partnering and collaborating to advance drug delivery innovation is essential, now more than ever, say industry experts from Boehringer-Ingelheim and Merck.
